Osimertinib Tops Standard EGFR-TKI for EGFR+ NSCLC

This article originally appeared here.
Share this content:
Osimertinib Tops Standard EGFR-TKI for <i>EGFR</i>&#43; NSCLC
Osimertinib Tops Standard EGFR-TKI for EGFR+ NSCLC

MONDAY, Nov. 20, 2017 (HealthDay News) -- For patients with previously untreated, epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC), treatment with osimertinib is associated with longer progression-free survival than a standard EGFR tyrosine kinase inhibitor (TKI), according to a study published online Nov. 18 in the New England Journal of Medicine to coincide with the European Society for Medical Oncology Asia 2017 Congress, held from Nov. 17 to 19 in Singapore.

Jean-Charles Soria, M.D., Ph.D., from the Gustave Roussy Cancer Campus and University Paris-Sud, and colleagues conducted a phase 3 trial involving 556 patients with previously untreated EGFR mutation-positive advanced NSCLC. Participants were randomized to receive osimertinib or standard EGFR-TKI.

The researchers found that median progression-free survival was significantly longer with osimertinib than EGFR-TKIs (18.9 versus 10.2 months; hazard ratio for disease progression or death, 0.46 [95 percent confidence interval, 0.37 to 0.57; P < 0.001]). The two groups had a similar objective response rate (80 and 76 percent, respectively; odds ratio, 1.27 [95 percent confidence interval, 0.85 to 1.90; P = 0.24]). The median response duration was 17.2 months with osimertinib and 8.5 months with standard EGFR-TKIs. Grade 3 or higher adverse events were less frequent with osimertinib (34 versus 45 percent).

"Osimertinib showed efficacy superior to that of standard EGFR-TKIs in the first-line treatment of EGFR mutation-positive advanced NSCLC, with a similar safety profile and lower rates of serious adverse events," the authors write.

The study was funded by AstraZeneca, the manufacturer of osimertinib.

Abstract
Full Text
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »